Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
15 Jul 2019
Historique:
received: 05 02 2019
accepted: 28 06 2019
entrez: 17 7 2019
pubmed: 17 7 2019
medline: 18 12 2019
Statut: epublish

Résumé

While multiagent chemotherapy has dramatically improved the prognosis of sarcoma, the novel chemotherapeutics have hardly developed over the past 30 years. Caffeine can induce apoptosis, delays in cell cycle progression and can enhance the cytocidal effects of anti-cancer agents. Citrate has been reported to enhance the cytocidal effect of cisplatin in gastric cancer in vitro. However its effect in sarcoma cells had not been reported. This study was designed to evaluate whether the addition of caffeine, citrate, or caffeine citrate to cisplatin improved its cytocidal effect (cell survival, proliferation, and apoptosis) on human osteosarcoma (HOS), human fibrosarcoma (HT1080) and murine osteosarcoma (LM8) cell lines. We also tested the various combinations in a mouse heterotopic transplantation model in vivo. In cell survival assay, combination index (CI) of caffeine citrate was calculated as a combination of anhydrous caffeine and citric acid, and the synergy was evaluated (CI < 1.0). In all cell lines, cisplatin combined with caffeine citrate significantly reinforced the anticancer effect compared with cisplatin alone, combination of cisplatin and anhydrous caffeine, and combination of cisplatin and citric acid. Moreover, CI was < 1.0 in all conditions. The anticancer agent reinforcement effect of caffeine citrate was synergy of anhydrous caffeine and citric acid. In cell proliferation and cell cycle assay revealed that caffeine citrate had most strong effect as a combination drug than caffeine and citric acid in inducing G0/G1 cell-cycle arrest with subsequent suppressed cell proliferation. In mitochondrial depolarization and caspase 3/7 activity assay revealed that caffeine citrate had most strong effect as a combination drug than caffeine and citric acid in apoptosis associated with decreased mitochondrial membrane potential. In vivo, three different drug concentrations were tested, and cisplatin combined with caffeine citrate was found to have the strongest antitumor effect. This is the first report demonstrating that caffeine citrate has a significantly greater potentiating effect on cisplatin than adding either caffeine or citric acid. The combination of cisplatin with caffeine citrate is a novel treatment that might hold promise for improving the outcome of osteosarcoma and fibrosarcoma, which up till now has generally not responded well to chemotherapy.

Sections du résumé

BACKGROUND BACKGROUND
While multiagent chemotherapy has dramatically improved the prognosis of sarcoma, the novel chemotherapeutics have hardly developed over the past 30 years. Caffeine can induce apoptosis, delays in cell cycle progression and can enhance the cytocidal effects of anti-cancer agents. Citrate has been reported to enhance the cytocidal effect of cisplatin in gastric cancer in vitro. However its effect in sarcoma cells had not been reported.
METHODS METHODS
This study was designed to evaluate whether the addition of caffeine, citrate, or caffeine citrate to cisplatin improved its cytocidal effect (cell survival, proliferation, and apoptosis) on human osteosarcoma (HOS), human fibrosarcoma (HT1080) and murine osteosarcoma (LM8) cell lines. We also tested the various combinations in a mouse heterotopic transplantation model in vivo. In cell survival assay, combination index (CI) of caffeine citrate was calculated as a combination of anhydrous caffeine and citric acid, and the synergy was evaluated (CI < 1.0).
RESULTS RESULTS
In all cell lines, cisplatin combined with caffeine citrate significantly reinforced the anticancer effect compared with cisplatin alone, combination of cisplatin and anhydrous caffeine, and combination of cisplatin and citric acid. Moreover, CI was < 1.0 in all conditions. The anticancer agent reinforcement effect of caffeine citrate was synergy of anhydrous caffeine and citric acid. In cell proliferation and cell cycle assay revealed that caffeine citrate had most strong effect as a combination drug than caffeine and citric acid in inducing G0/G1 cell-cycle arrest with subsequent suppressed cell proliferation. In mitochondrial depolarization and caspase 3/7 activity assay revealed that caffeine citrate had most strong effect as a combination drug than caffeine and citric acid in apoptosis associated with decreased mitochondrial membrane potential. In vivo, three different drug concentrations were tested, and cisplatin combined with caffeine citrate was found to have the strongest antitumor effect.
CONCLUSIONS CONCLUSIONS
This is the first report demonstrating that caffeine citrate has a significantly greater potentiating effect on cisplatin than adding either caffeine or citric acid. The combination of cisplatin with caffeine citrate is a novel treatment that might hold promise for improving the outcome of osteosarcoma and fibrosarcoma, which up till now has generally not responded well to chemotherapy.

Identifiants

pubmed: 31307409
doi: 10.1186/s12885-019-5891-y
pii: 10.1186/s12885-019-5891-y
pmc: PMC6631922
doi:

Substances chimiques

Antineoplastic Agents 0
Central Nervous System Stimulants 0
Citrates 0
Caffeine 3G6A5W338E
Cisplatin Q20Q21Q62J
caffeine citrate U26EO4675Q

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

689

Références

Cancer Res. 1999 Sep 1;59(17):4375-82
pubmed: 10485486
J Bone Joint Surg Br. 2002 Jan;84(1):88-92
pubmed: 11837839
Cancer Res. 2003 Jan 1;63(1):80-5
pubmed: 12517781
Cancer Res. 2003 Aug 1;63(15):4396-401
pubmed: 12907610
J Cancer Res Clin Oncol. 1992;118(8):567-9
pubmed: 1517277
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
J Bone Joint Surg Am. 2004 Dec;86(12):2686-93
pubmed: 15590854
Radiat Res. 1978 Nov;76(2):292-307
pubmed: 156382
Genes Dev. 2005 Jun 1;19(11):1294-305
pubmed: 15901672
IARC Monogr Eval Carcinog Risks Hum. 1991;51:1-513
pubmed: 1674554
J Bone Joint Surg Am. 2007 Jun;89(6):1399-407
pubmed: 17545444
Skin Pharmacol. 1991;4(4):286-90
pubmed: 1789989
Curr Mol Med. 2008 Mar;8(2):138-47
pubmed: 18336294
Int J Cancer. 2009 Jul 1;125(1):229-34
pubmed: 19330840
Anticancer Res. 2009 Apr;29(4):1249-54
pubmed: 19414371
Expert Opin Drug Deliv. 2009 Dec;6(12):1311-21
pubmed: 19761419
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Carcinogenesis. 2010 Jun;31(6):984-93
pubmed: 20142415
Pediatr Radiol. 2011 Feb;41(2):227-36
pubmed: 20814672
Int J Oncol. 2011 Aug;39(2):465-72
pubmed: 21617855
Cell. 2011 Aug 19;146(4):607-20
pubmed: 21854985
Biol Pharm Bull. 2012;35(3):400-7
pubmed: 22382328
Anticancer Res. 2012 Sep;32(9):3643-9
pubmed: 22993301
Eur J Cancer. 2013 Feb;49(3):684-95
pubmed: 23079473
J Cell Biochem. 2013 Nov;114(11):2454-60
pubmed: 23696238
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336
Oncol Res Treat. 2014;37(6):355-62
pubmed: 24903768
J Clin Oncol. 1989 Sep;7(9):1208-16
pubmed: 2504890
Exp Hematol Oncol. 2015 Feb 11;4:5
pubmed: 25937999
J Clin Oncol. 2015 Sep 20;33(27):3029-35
pubmed: 26304877
Life Sci. 1989;45(11):947-61
pubmed: 2677570
J Clin Oncol. 2016 Jul 1;34(19):2294-302
pubmed: 27185843
J Natl Compr Canc Netw. 2016 Jun;14(6):758-86
pubmed: 27283169
Anticancer Res. 2017 Mar;37(3):1005-1011
pubmed: 28314258
J Pharmacol Exp Ther. 1988 Nov;247(2):603-8
pubmed: 3183956
Proc Natl Acad Sci U S A. 1982 May;79(9):2942-6
pubmed: 6953438
J Clin Oncol. 1995 Jul;13(7):1537-45
pubmed: 7602342
J Clin Oncol. 1993 Jul;11(7):1269-75
pubmed: 8315424
J Clin Oncol. 1993 Jul;11(7):1276-85
pubmed: 8315425
Anticancer Res. 1998 Jan-Feb;18(1B):657-66
pubmed: 9584049
Clin Orthop Relat Res. 1999 Jan;(358):27-35
pubmed: 9973973

Auteurs

Kensaku Abe (K)

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Norio Yamamoto (N)

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Katsuhiro Hayashi (K)

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Akihiko Takeuchi (A)

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan. a_take@med.kanazawa-u.ac.jp.

Hiroyuki Tsuchiya (H)

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH